Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 30
Filter
1.
Rev. méd. Chile ; 148(11)nov. 2020.
Article in English | LILACS | ID: biblio-1389254

ABSTRACT

ABSTRACT MEK- and BRAF-inhibitors trametinib and dabrafenib are successfully used for BRAF-mutated, metastasizing melanoma, but these compounds may induce side effects. We report a 50 years old female with BRAF-mutated metastasizing melanoma who received trametinib (2 mg/d) and dabrafenib (200 mg/d) after using interferon without benefit. Shortly after starting trametinib/dabrafenib, she experienced an inability to abduct the left eye. Eight days after starting this therapy the patient experienced loss of appetite, vomiting, diarrhea, vertigo, and fever of 40°C. Two days later she experienced visual loss, requiring permanent support for her daily activities. Two further days later myoglobinuria appeared in the absence of myalgias or muscle weakness but accompanied by marked tiredness and inactivity. She could not eat or drink during four days prior to admission. The patient suspected an adverse effect of trametinib/dabrafenib and discontinued it 2 days prior to admission. Thereafter, she experienced an almost complete remission of the deficits except for ocular muscle weakness and visual impairment.


Los inhibidores de MEX and BRAF como trametinib y dabrafenib se usan en el melanoma metastásico con mutación BRAF, pero pueden tener efectos secundarios. Informamos una paciente de 50 años con un melanoma metastásico con la mutación BRAF que recibió trametinib (2 mg/día) y dabrafenib (200 mg/día) después de usar interferón sin beneficio. Después de iniciar esta terapia la paciente notó una incapacidad de abducir el ojo izquierdo. Ocho días después de iniciar el tratamiento, tuvo falta de apetito, vómitos, diarrea, vértigo y fiebre de 40°C. Dos días después notó pérdida de su agudeza visual, requiriendo asistencia para efectuar sus actividades de vida diaria. Dos días después apareció coluria, en ausencia de mialgias o debilidad muscular, pero acompañadas de fatiga. Ella no pudo comer o tomar líquidos por cuatro días antes de ingresar al hospital. La paciente sospechó que estaba experimentando efectos secundarios de los medicamentos y los suspendió dos días antes del ingreso, experimentando una casi completa remisión de sus síntomas, con excepción de la debilidad de musculatura ocular y déficit visual.


Subject(s)
Female , Humans , Middle Aged , Rhabdomyolysis , Skin Neoplasms , Renal Insufficiency , Oximes , Pyridones/adverse effects , Pyrimidinones , Rhabdomyolysis/chemically induced , Skin Neoplasms/drug therapy , Vision Disorders/chemically induced , Antineoplastic Combined Chemotherapy Protocols , Proto-Oncogene Proteins B-raf/genetics , Imidazoles , Mutation
3.
Rev. chil. pediatr ; 84(1): 68-71, feb. 2013. ilus
Article in Spanish | LILACS | ID: lil-677321

ABSTRACT

Introduction: rhabdomyolysis is a potentially lethal syndrome characterized by disintegration of striated muscle fibers. In children Rhabdomyolysis is caused mostly by trauma, nonketotic hyperosmolar coma, viral myositis, dystonia and malignant hyperthermia. Case report: a 14 year old male was brought into the emergency room because of a decreased level of consciousness following alcohol and cannabis. An initial assessment indicated the presence of hypothermia and a Glasgow Coma Scale of 9. A blood biochemical analysis showed a mixed acidosis and CPK levels of 12260 U/L (CK-MB 132 U/L). After diagnosing alcohol induced coma and rhabdomyolysis, intravenous fluids and urinary alkalinization are administered. The patient presented a rapid neurological improvement reaching normal within 12 hours. He remained normotensive, adequate diuresis, negative balances, normal blood gas values and urine test strips presented no pathological changes. A maximum level of serum CPK was observed 24 hours after ingestion (20820 U/L), with subsequent decline to 6261 U/L at day 5, once he was discharged. Discussion: alcohol poisoning is a rare cause of rhabdomyolysis in pediatrics. The main therapeutic goal is to prevent acute renal failure, aggressive fluid therapy and urine alkalinization then must be administered, monitoring possible electrolyte abnormalities and the presence of myoglobinuria. In conclusion, rhabdomyolysis is one of the possible complications after alcohol poisoning. Given its potential morbidity, it should always be considered.


Introducción: la rabdomiolisis es un síndrome potencialmente letal caracterizado por la destrucción de fibras musculares estríadas. En niños es producido fundamentalmente por traumatismos, coma hiperosmolar no cetósico, miositis vírica, distonía o hipertermia maligna. Caso clínico: varón de 14 años que es traído al servicio de Urgencias por disminución del nivel de conciencia secundaria a consumo de alcohol y cannabis. En la valoración inicial en nuestro centro se constatan hipotermia y una puntuación según la escala de Glasgow de 9. En el análisis bioquímico sanguíneo destacan una acidosis mixta y niveles de CPK de 12.260 U/L (CK-MB 132 U/L). Con los diagnósticos de coma etílico y rabdomiolisis se inicia administración de fluidoterapia intravenosa y alcalinización urinaria. Presentó una rápida mejoría neurológica con normalización en las primeras 12 h. Se mantuvo normotenso, con adecuada diuresis, balances negativos, normalización de los valores gasométricos y tiras reactivas de orina seriadas sin hallazgos patológicos. Se objetivó un nivel máximo de CPK sérica 24 h tras la ingesta (20.820 U/L), con descenso posterior hasta 6.261U/L a los 5 días, cuando se dio de alta. Discusión: la intoxicación etílica constituye una causa infrecuente de rabdomiolisis en pediatría. El principal objetivo terapéutico es evitar el fracaso renal agudo, por lo que se deben iniciar fluidoterapia agresiva y eventual alcalinización de la orina, manteniendo monitorizados las posibles alteraciones electrolíticas así como la presencia de mioglobinuria. En conclusión, la rabdomiolisis es una de las posibles complicaciones de la intoxicación etílica. Dada su potencial morbimortalidad, siempre debe ser tenida en cuenta.


Subject(s)
Humans , Male , Adolescent , Alcoholic Beverages/adverse effects , Fluid Therapy/methods , Rhabdomyolysis/chemically induced , Rhabdomyolysis/therapy , Creatine Kinase/analysis , Acute Disease , Renal Insufficiency/prevention & control , Alcoholic Intoxication/therapy , Emergencies
4.
São Paulo med. j ; 131(6): 432-435, 2013. tab
Article in English | LILACS | ID: lil-697418

ABSTRACT

CONTEXT: Tricyclic antidepressive agents are widely used in suicide attempts and present a variety of deleterious effects. Rhabdomyolysis is a rare complication of such poisoning. CASE REPORT: A 55-year-old woman ingested 120 pills of 25 mg clomipramine in a suicide attempt two days before admission. After gastric lavage in another emergency department on the day of intake, 80 pills were removed. On admission to our department, she was disoriented, complaining of a dry mouth and tremors at the extremities. An electrocardiogram showed a sinus rhythm with narrow QRS complexes. Laboratory results showed high creatine phosphokinase (CK = 15,094 U/l on admission; normal range = 26 to 140 U/l), hypocalcemia, slightly increased serum transaminases and mild metabolic acidosis. The patient's medical history included depression with previous suicide attempts, obsessive-compulsive disorder, hypothyroidism and osteoporosis. She presented cardiac arrest with pulseless electric activity for seven minutes and afterwards, without sedation, showed continuous side-to-side eye movement. She developed refractory hypotension, with need for vasopressors. Ceftriaxone and clindamycin administration was started because of a hypothesis of bronchoaspiration. The patient remained unresponsive even without sedation, with continuous side-to-side eye movement and a decerebrate posture. She died two months later. Rhabdomyolysis is a very rare complication of poisoning due to tricyclic drugs. It had only previously been described after an overdose of cyclobenzaprine, which has a toxicity profile similar to tricyclic drugs. CONCLUSIONS: Although arrhythmia is the most important complication, rhabdomyolysis should be investigated in cases of clomipramine poisoning. .


CONTEXTO: Antidepressivos tricíclicos são amplamente utilizados em tentativas de suicídio e apresentam diversos efeitos deletérios, sendo a rabdomiólise uma complicação rara dessa intoxicação. RELATO DO CASO: Uma mulher de 55 anos ingeriu 120 comprimidos de clomipramina de 25 mg numa tentativa de suicídio dois dias antes da admissão. Após lavagem gástrica em outro serviço de urgência no dia da ingestão, 80 comprimidos foram retirados. Na admissão em nosso serviço, a paciente estava desorientada, queixando-se de boca seca e tremores de extremidades. O eletrocardiograma mostrou ritmo sinusal com complexos QRS estreitos. Exames laboratoriais evidenciaram aumento de creatinofosfoquinase (CK = 15.094 U/L na admissão; intervalo da normalidade = 26 a 140 U/L), hipocalcemia, discreto aumento das transaminases e leve acidose metabólica. Antecedentes pessoais incluíam depressão com tentativas de suicídio prévias, transtorno obsessivo compulsivo, hipotireoidismo e osteoporose. A paciente apresentou parada cardiorrespiratória com atividade elétrica sem pulso por sete minutos e, posteriormente, sem sedação, foi observado olhar em varredura. A paciente evoluiu com hipotensão refratária, necessitando de vasopressores. Ceftriaxone e clindamicina foram iniciados pela hipótese de broncoaspiração. A paciente permaneceu irresponsiva mesmo sem sedação, com olhar em varredura contínuo e postura descerebrada. A paciente evoluiu para óbito dois meses após. Rabdomiólise é uma complicação rara da intoxicação por tricíclicos, e só foi descrita em overdose de ciclobenzaprina, a qual tem um perfil de toxicidade semelhante aos tricíclicos. CONCLUSÕES: Apesar de as arritmias serem as complicações mais temidas, ...


Subject(s)
Female , Humans , Middle Aged , Antidepressive Agents, Tricyclic/poisoning , Clomipramine/poisoning , Rhabdomyolysis/chemically induced , Creatine Kinase/blood , Fatal Outcome , Suicide, Attempted
5.
Annals of Saudi Medicine. 2012; 32 (3): 309-311
in English | IMEMR | ID: emr-128513

ABSTRACT

Toxic epidermal necrolysis represents an immunologic reaction to a foreign antigen and is most often caused by drugs. Atorvastatin, a blood cholesterol-lowering agent, is a recognized cause of rhabdomyolysis; while naproxen, a widely used nonsteroidal anti-inflammatory drug, is a known cause of photo-induced skin lesions. We report the first fatal case of drug-induced toxic epidermal necrolysis associated with severe muscle necrosis due to the use of a nonsteroidal anti-inflammatory drug and a statin with very high levels of creatine phosphokinase leading to acute kidney injury, disseminated intravascular coagulation, and complete skin necrosis leading to death


Subject(s)
Humans , Female , Rhabdomyolysis/chemically induced , Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Naproxen/adverse effects , Heptanoic Acids , Pyrroles , Creatine Kinase , Disseminated Intravascular Coagulation
6.
Rev. méd. Chile ; 139(4): 480-483, abr. 2011. ilus
Article in Spanish | LILACS | ID: lil-597644

ABSTRACT

Rhabdomyolysis caused by cocaine abuse is multifactorial, involving tissue ischemia secondary to vasoconstriction and cellular damage caused by the drug. Renal failure may or may be not associated to rhabdomyolysis. We report a 41-year-old male admitted with a severe rhabdomyolysis after a cocaine overdose. In spite of a vigorous hydration and alkalization, he developed acute renal failure. Renal function recovered after several weeks of dialysis.


Subject(s)
Adult , Humans , Male , Acute Kidney Injury/chemically induced , Cocaine-Related Disorders/complications , Cocaine/adverse effects , Rhabdomyolysis/chemically induced , Drug Overdose
7.
Journal of Korean Medical Science ; : 1634-1637, 2011.
Article in English | WPRIM | ID: wpr-112907

ABSTRACT

HMG-CoA reductase inhibitors (statins) are widely used to treat hypercholesterolemia. Among the adverse effects associated with these drugs are statin-associated myopathies, ranging from asymptomatic elevation of serum creatine kinase to fatal rhabdomyolysis. Fluvastatin-induced fatal rhabdomyolysis has not been previously reported. We describe here a patient with liver cirrhosis who experienced fluvastatin-induced fatal rhabdomyolysis. This patient had been treated with simvastatin (20 mg/day) for coronary artery disease and was switched to fluvastatin (20 mg/day) 10 days before admission. He was also taking aspirin, betaxolol, candesartan, lactulose, and entecavir. Rhabdomyolysis was complicated and continued to progress. He was treated with massive hydration, urine alkalization, intravenous furosemide, and continuous renal replacement therapy for acute renal failure, but eventually died due to rhabdomyolysis complicated by hepatic failure. In conclusion, fluvastatin should be used with caution in patients with liver cirrhosis, especially with other medications metabolized with CYP2C9.


Subject(s)
Humans , Male , Middle Aged , Coronary Artery Disease/complications , Fatal Outcome , Fatty Acids, Monounsaturated/administration & dosage , Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage , Indoles/administration & dosage , Liver Cirrhosis/complications , Rhabdomyolysis/chemically induced , Simvastatin/administration & dosage
8.
Arq. bras. endocrinol. metab ; 53(3): 383-386, Apr. 2009. tab
Article in English | LILACS | ID: lil-517685

ABSTRACT

Clinical and most often moderate skeletal muscle involvement is a frequent problem in adults with hypothyroidism, and includes a number of different manifestations. Severe involvement with rhabdomyolysis, however, is very rare, and only a few cases have been reported to date, most of them with an additional factor of muscle injury. We described a patient with stage 3 chronic kidney disease who presented with rhabdomyolysis while taking fenofibrate, and was found to have hypothyroidism. We also highlighted the importance of excluding the diagnosis of thyroid dysfunction before treatment with lipid-lowering agents.


Manifestações musculoesqueléticas variadas e de moderada intensidade são comuns em adultos com hipotireoidismo. No entanto, o envolvimento muscular grave, caracterizado por rabdomiólise, é incomum. Até o momento, poucos casos foram descritos na literatura, e a maior parte deles em associação com um fator adicional de dano muscular. Descrevemos um paciente com doença renal crônica (estádio 3) que se apresentou com rabdomiólise durante o tratamento com fenofibrato e cuja investigação adicional evidenciou hipotireoidismo primário. Enfatizamos, ainda, a importância da exclusão de disfunção tireoidiana antes de iniciar terapia com agentes hipolipemiantes.


Subject(s)
Humans , Male , Middle Aged , Hypolipidemic Agents/adverse effects , Hypothyroidism/complications , Fenofibrate/adverse effects , Renal Insufficiency, Chronic/complications , Rhabdomyolysis/chemically induced , Hypertriglyceridemia/drug therapy
10.
Rev. Soc. Bras. Clín. Méd ; 6(6): 273-275, nov.-dez. 2008.
Article in Portuguese | LILACS | ID: lil-502530

ABSTRACT

JUSTIFICATIVA E OBJETIVOS: A habilidade das estatinas em reduzir a morbimortalidade dos pacientes com dislipidemia está bem estabelecida. Os efeitos adversos são geralmente leves e temporários. As complicações mais importantes e indesejáveis são a elevação das enzimas hepáticas, miopatia e rabdomiólise, que se caracteriza por necrose muscular, mioglobinúria e insuficiência renal aguda. No geral, as estatinas estão relacionadas a um pequeno risco de miopatia que pode progredir para rabdomiólise fatal ou não fatal. A incidência está relacionada com a dose e o uso concomitante de agentes que compartilham a mesma via metabólica das estatinas. A insuficiência renal aguda é a mais temida complicação da rabdomiólise e a principal causa de óbito. O reconhecimento e tratamento precoce podem prevenir a progressão da rabdomiólise. RELATO DO CASO: Paciente do sexo masculino, 57 anos, sem história prévia de doença renal evolui com insuficiência renal aguda e rabdomiólise, induzida por alta dose de estatina (sinvastatina 80 mg/dia). CONCLUSÃO: Os clínicos devem estar alerta para as interações medicamentosas das estatinas a fim de minimizar o risco de miopatia. Ao prescrever estatinas o médico deve considerar as comorbidades e fatores de risco, incluindo uso de múltiplas medicações, e iniciar estatina com a menor dose possível em idosos. Se houver suspeita deste efeito adverso, o fármaco deve ser suspenso.(AU)


BACKGROUND AND OBJECTIVES: The ability of statins to reduce the risk of cardiovascular morbimortality in patients with dyslipidemia is well established. The adverse effects associated with statins are usually mild and transient. The most noteworthy adverse effects associated with statins are elevations in liver transaminasis, myopathy and rhabdomyolysis, which is characterized by massive muscle necrosis, myoglobinuria and acute renal failure. In general, statins are associated with a very small risk of myopathy (with may progress to fatal or nonfatal rhabdomyolysis). The incidence is dose related and is increased when statins are used in combination with agents that share common metabolic pathways. Acute renal failure is the most serious complication of rhabdomyolysis and the main cause of death. Early recognition and treatment may prevent the progression of rhabdomyolysis. CASE REPORT: A 57 year-old-man, with no history of renal dysfunction presented with acute renal failure and rhabdomyolysis induced by high-dose statin (simvastatin 80 mg/day). CONCLUSION: Clinicians should be alert for drug-drug interactions to minimize the risk of myopathy. The prescribing physician should consider the co-morbid risk factors, including polypharmacy, and initiate statin at a lower dose in the elderly. If rhabdomyolysis is suspected the statin therapy should be withdrawn.(AU)


Subject(s)
Humans , Male , Middle Aged , Rhabdomyolysis/chemically induced , Hydroxymethylglutaryl-CoA Reductase Inhibitors/toxicity , Renal Insufficiency/chemically induced , Urine/chemistry , Risk Factors , Diuresis , Fluid Therapy/instrumentation
11.
Article in English | IMSEAR | ID: sea-86177

ABSTRACT

Hair dye ingestion is an uncommon form of poisoning in the west, however, in some parts of the world such as East Africa and Indian Sub-continent it is not uncommon. The main component of hair dye causing toxicity is Paraphenylenediamine (PPD). This compound has been found to cause angioneurotic edema, rhabdomyolysis and renal failure. We present a case of hair dye poisoning who presented with respiratory distress due to laryngeal edema and later developed trismus and carpopedal spasm. This case report highlights the combined toxicities of sodium EDTA and PPD.


Subject(s)
Adult , Edema/chemically induced , Edetic Acid/adverse effects , Female , Hair Dyes/adverse effects , Humans , Laryngeal Diseases/chemically induced , Phenylenediamines/poisoning , Rhabdomyolysis/chemically induced , Trismus/chemically induced
12.
Arq. neuropsiquiatr ; 65(3b): 834-837, set. 2007. ilus
Article in English | LILACS | ID: lil-465190

ABSTRACT

The rosuvastatin inducing rhabdomyolysis in McArdle disease (MD) has not been reported to date. A 35-years-old man had exercise intolerance, muscular fatigue and cramps during physical activity since infancy. He presented severe rhabdomyolysis episode with seizure and coma after use of rosuvastatin. The investigation showed increased serum creatinekinase levels and the forearm ischemic exercise did not increased venous lactate. The muscle biopsy showed subsarcolemmal and central acummulation of glycogen and absence of the myophosphorylase enzyme. The statin induced myopathy is discussed and the danger of its use in MD is emphasized.


Rosuvastatina induzindo rabdomiólise na doença de McArdle (MD) não foi relatada até o momento. Descrevemos o caso de um homem de 35 anos que desde a infância apresentava sintomas de intolerância aos exercícios, fadiga muscular e cãibras durante o esforço físico, porém após o uso de rosuvastatina apresentou episódio de rabdomiólise com crises convulsivas e coma. A investigação mostrou creatinoquinase sérica elevada e teste do esforço isquêmico sem aumento no lactato venoso. A biópsia muscular revelou acúmulo central e subsarcolemal de glicogênio nas fibras e ausência da enzima miofosforilase. Discutimos as estatinas induzindo miopatia, enfatizando o risco do seu uso na MD.


Subject(s)
Adult , Humans , Male , Fluorobenzenes/adverse effects , Glycogen Storage Disease Type V/drug therapy , Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects , Pyrimidines/adverse effects , Rhabdomyolysis/chemically induced , Sulfonamides/adverse effects , Fluorobenzenes/therapeutic use , Glycogen Storage Disease Type V/blood , Glycogen Storage Disease Type V/pathology , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Pyrimidines/therapeutic use , Rhabdomyolysis/blood , Rhabdomyolysis/pathology , Sulfonamides/therapeutic use
14.
Arq. bras. cardiol ; 85(supl.5): 9-14, out. 2005. tab, graf
Article in Portuguese | LILACS | ID: lil-418867

ABSTRACT

As estatinas são agentes hipolipemiantes que exercem os seus efeitos através da inibição da HMG-CoA redutase, enzima fundamental na síntese do colesterol, levando a uma redução do colesterol tecidual e um conseqüente aumento na expressão dos receptores de LDL. Existem consideráveis diferenças entre as estatinas, no que tange às propriedades farmacocinéticas, bem como ao coeficiente de hidrofilicidade, via hepática de metabolização (especialmente, do citocromo P450 e isoenzimas), meia-vida plasmática e eficácia na redução lipídica. As estatinas também podem diferir na capacidade de interação com outras drogas que utilizam a mesma via de metabolização. Recentemente, muitos efeitos pleiotrópicos têm sido relatados com estas drogas, bem como propriedades antiinflamatórias, melhora na função endotelial e benefícios na hemostasia.


Subject(s)
Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacokinetics , Cholesterol, LDL/metabolism , Drug Interactions , Muscular Diseases/chemically induced , Liver Diseases/chemically induced , Aryl Hydrocarbon Hydroxylases/metabolism , Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects , Hydroxymethylglutaryl-CoA Reductase Inhibitors/chemistry , Rhabdomyolysis/chemically induced
15.
Arq. bras. cardiol ; 85(supl.5): 34-35, out. 2005.
Article in Portuguese | LILACS | ID: lil-418873

ABSTRACT

Monoterapia para o tratamento das dislipidemias é frequentemente insuficiente para o alcance das metas recomendadas pelas diretrizes. Entretanto, nos últimos anos, o uso de terapia combinada tem se apresentado como uma nova opção em muitos casos. Uma revisão de 36 estudos envolvendo a combinação de estatinas com fibratos apresentou 29 casos de rabdomiólise e uma prevalência geral de miopatia de 0,12 por cento. A combinação de estatinas com o genfibrozil parece causar mais rabdomiólise que com os fibratos de nova geração (especialmente quando comparado com fenofibrato ou bezafibrato). Idade avançada, diabetes, mulheres, medicações concomitantes, disfunção renal, consumo excessivo de álcool, exercícios, traumatismos e cirurgias estão também associados com maior risco de efeitos adversos.


Subject(s)
Humans , Male , Female , Clofibric Acid/adverse effects , Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects , Age Factors , Clofibric Acid/therapeutic use , Drug Interactions , Drug Therapy, Combination , Dyslipidemias/drug therapy , Gemfibrozil/adverse effects , Gemfibrozil/therapeutic use , Hypertriglyceridemia/drug therapy , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Myositis/chemically induced , Rhabdomyolysis/chemically induced , Sex Factors
16.
Arq. bras. cardiol ; 85(supl.5): 42-44, out. 2005.
Article in Portuguese | LILACS | ID: lil-418875

ABSTRACT

A rabdomiólise é incomum, mas é o efeito adverso mais sério observado na terapia hipolipemiante com estatinas. A ocorrência de rabdomiólise fatal reportada nos Estados Unidos desde a introdução das estatinas no mercado, na década de 1980, foi muito rara (0,15 casos por milhão de pacientes tratados por ano). Entretanto, a miopatia, definida como: sintomas musculares associados com elevações da CK; é muito mais comum (1 por cento-5 por cento). Os mecanismos de miopatia mediada por estatinas não estão totalmente compreendidos. Várias hipóteses têm sido propostas: diminuição dos níveis celulares de isoprenóides e ubiquinona, incremento de apoptose, mudanças nos canais de cloro diminuindo a hiperpolarização da membrana celular e alterações da permeabilidade da membrana celular. Interação com outras drogas, e alterações metabólicas pré-existentes podem predispor a miopatia.


Subject(s)
Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects , Rhabdomyolysis/chemically induced , Apoptosis/drug effects , Cyclosporine/adverse effects , Cyclosporine/metabolism , Creatine Kinase/analysis , Drug Interactions , Cardiovascular Diseases/prevention & control , Hydroxymethylglutaryl-CoA Reductase Inhibitors/metabolism , Rhabdomyolysis/metabolism
17.
Arq. bras. endocrinol. metab ; 49(4): 604-609, ago. 2005. tab
Article in Portuguese | LILACS | ID: lil-414782

ABSTRACT

A rabdomiólise tem sido motivo de publicação na literatura médica há mais de 50 anos. Nas últimas décadas, com o advento das estatinas, usadas na prevenção primária e secundária da doença cardiovascular, este assunto volta como importante complicação, muitas vezes fatal, do uso desta classe de drogas. A rabdomiólise associada ao uso das estatinas ocorre principalmente devido a associações medicamentosas. A seguir, descreveremos um caso de uma paciente em uso de altas doses de Sinvastatina, devido à doença aterosclerótica difusa, que desenvolveu quadro compatível com rabdomiólise resultando em óbito.


Subject(s)
Aged , Female , Humans , Acute Kidney Injury , Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects , Rhabdomyolysis/chemically induced , Simvastatin/adverse effects , Arteriosclerosis/drug therapy , Drug Interactions , Fatal Outcome , Simvastatin/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL